Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

- Company Focused on Commercialization in 2008 -

FREMONT, Calif., May 15 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced financial results for the first quarter ended March 31, 2008, and provided an update on recent corporate and clinical developments.

"During the first quarter of 2008, we demonstrated significant clinical and commercialization progress in each of our diagnostic programs. These programs target significant unmet clinical needs and present attractive revenue opportunities. It is an exciting time as we explore strategic business development options that are synergistic with our Quest Diagnostics' alliance," said Gail Page, President and CEO of Vermillion.

The Company plans to finalize its clinical study examining the Ovarian Tumor Triage Test, now named OVA1(TM), and submit OVA1 to the U.S. Food and Drug Administration (FDA) in the second quarter of this year. Additionally, Vermillion is working on clinical studies and building market awareness of the PAD blood test, now named VASCLIR(TM) the PAD test. Throughout the remainder of 2008, the Company will focus on commercialization efforts.

First Quarter 2008 Financial Results

As a result of the November 13, 2006 sale of its former instrument business to Bio-Rad Laboratories, the Company does not anticipate significant revenue until its diagnostic tests are commercialized. During the first quarter of 2008, products revenue of $5,000 was generated from the sale of thrombotic thrombocytopenic purpura ("TTP") test component materials to The Ohio State University Research Foundation ("OSU").

Total operating expenses decreased in the first quarter of 2008 to $4.6 million,
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2009)...,, CAMBRIDGE, Mass., Nov. 7, Re...ochemistry scored top marks this evening, as Tim K...Song and Quan (Jack) Chen of Audubon, PA received ...e 2009 Siemens Competition in Math, Science & ...ce competition. ,, ( http://www.newscom.com/cg...
(Date:11/6/2009)...,, QUINCY, Mass., Nov. 6 Myrian...biotech developer and manufacturer of renewable b...preferred technology provider Uhde GmbH, one of th... "Uhde"), announced an alliance for the engineerin...,s biobased Succinic Acid plants based on renewabl...
(Date:11/6/2009)...,, CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Onc...lytics" or the "Company") today announced updated ...SIN(R) in patients with sarcomas metastatic to the...Connective Tissue Oncology Society Meeting held in...he poster presentation, entitled "A Phase II Study...
(Date:11/5/2009)...,, GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstC...ced its financial results for the third quarter en... of $3.6 million ($0.04 per share) for the three m...oss of $6.8 million ($0.08 per share) in the compa...eptember 30, 2009, GenVec,s net loss was $14.1 mil...
Breaking Biology Technology:Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 3Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 4Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 5Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 6Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... 17 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ..., today announced that its lead product candidate,...uct designation for the treatment of,small cell lu...designation,is based on a recommendation from the ...the European Medicines Agency (EMEA). Picoplatin ...
...lt announced today that,the Henry C. Witelson Ocul...ealth Centre has purchased a Personal Archive bios... in Montreal, Quebec. GenVault technology will be... in determining the mechanisms underlying eye canc...for developing new approaches for,treatment. These...
...ea Pharmaceuticals,Inc. announced today that BC De...diagnostic test, is now available from Panacea Lab...at should facilitate the identification,of recurre...ncer. Panacea,Laboratories, a division of Panacea ...aboratory Improvement Amendments of 1988 (CLIA). T...
Other Biology Technology:Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 2Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 3Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 4McGill University Purchases GenVault's Personal Archive System to Manage Rare Cancer Samples 2Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 2Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 3Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 4
(Date:11/4/2009)...ity of North Carolina at Chapel Hill School of Med...sco have developed and experimentally tested a tec... drugs. , The researchers developed a computatio...s of all known drugs are to the naturally occurrin...se targets within the cell. In a study published t...
(Date:11/3/2009)...ore than 25 years, all attempts at culturing pearl...n unsuccessfuluntil now. For the first time, novel...ded (nucleated) and non-beaded cultured pearls fro...s from Florida Atlantic University,s Harbor Branch...o years of research and experimentation, Drs. Hcto...
(Date:11/3/2009)...as 28 percent less likely to become pregnant and h...that earned a Michigan State University professor ..., a researcher in the MSU College of Human Medicin...ductive Biology, focused on data of nearly 50,000 ...Luke,s findings, which also can be applied to wome...
Breaking Biology News(10 mins):Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3MSU researcher: Obesity significantly cuts odds of successful pregnancy 2Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 55970 1Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 55970 2Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market Notes Frost 26 Sullivan 55968 1Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market Notes Frost 26 Sullivan 55968 2Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market Notes Frost 26 Sullivan 55968 3TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 55966 1TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 55966 2
...discovered that human embryonic stem cell lines ac...me. , The findings do not limit the utility of th...ure clinical applications, the researchers say, bu...em cell lines for genetic changes and to study how... researchers, work is described in the Sept. 4 onl...
...s in India has risen in response to a 20-fold drop...ording to an article in the Nov. 15 issue of Clini... introduction of generic drugs into the country ha...of the cheaper cost, the article states. , Many of...g in India have been unable to obtain treatment du...
... people with compromised immune systems may be fea...s, who demonstrated their approach could protect a...same population of immune cells that HIV destroys ...ren,s Hospital of Pittsburgh researchers, working ...ity of Pittsburgh and Louisiana State University, ...
Other Biology News:Embryonic stem cells accrue genetic changes 2Embryonic stem cells accrue genetic changes 3Embryonic stem cells accrue genetic changes 4HIV mortality in India drops with introduction of generic antiretroviral therapy 2New vaccine platform may fight infections with causes from influenza to bioterrorism 2New vaccine platform may fight infections with causes from influenza to bioterrorism 3
Immulon 4 HBX 1x12 Strip from Thermo Scientific
Perfusion Pressure Kit - 8 channel from AutoMate Scientific, Inc
Nar I from Promega
Chicken Anti-UCK2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: